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Summary. Despite the findings in randomized trials of a sig- 
nificant effect of angiotensin-converting enzyme (ACE) in- 
hibitors in reducing morbidity and mortality of patients with 
symptomatic left ventricutar dysfunction, the morbidity and 
mortality of these patients remains relatively high. One po- 
tential strategy to further improve morbidity and mortality 
in these patients is blockade of aldosterone. Many clinicians 
have assumed that ACE inhibitors would block both angio- 
tensin II and aldosterone. However, there are data to suggest 
that aldosterone production may "escape" despite the use of 
an ACE inhibitor. An escape of aldosterone production has 
several important consequences, including: sodium reten- 
tion, potassium and magnesium loss, myocardial collagen 
production, ventricular hypertrophy, myocardial norepi- 
nephrine release, endothelial dysfunction, and a decrease in 
serum high density lipoprotein cholesterol. Due to the poten- 
tial importance of these mechanisms, the finding that there 
is a significant correlation between aldosterone production 
and mortality in patients with heart failure, as well as evi- 
dence that an aldosterone antagonist, spironolactone, when 
administered to patients with heart failure treated with con- 
ventional therapy including an ACE inhibitor results in in- 
creased diuresis and symptomatic improvement, an inter- 
national prospective multicenter study has been organized, 
the Randomized Aldactone Evaluation Study (RALES Pilot 
Study), to evaluate the safety of blocking the effects of aldo- 
sterone in patients with heart failure treated with an ACE 
inhibitor. 
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Large-scale randomized trials such as the Coopera- 
tive North Scandinavian Enalapril Survival Study 
(Consensus) [1], Studies of Left Ventricular Dysfunc- 
tion (SOLVD) Treatment  Trial [2], Vasodilator-Heart 
Failure Trial (V-HeFT-II)  [3], Survival After Left 
Ventricular Enlargement (SAVE) [4], and Acute In- 
farction Ramipril Efficacy (AIRE) Study [5], have 
confirmed the effectiveness of angiotensin-converting 
enzyme (ACE) inhibitors in reducing total mortality 
and morbidity in patients with symptomatic left ven- 
tricular dysfunction early and late postinfarction as 
well as in chronic heart  failure. There is also evidence 
suggesting that  ACE inhibitors may have an effect in 
reducing the incidence of recurrent  myocardial in- 
farction in patients with left ventricular dysfunction 
[4,6]. On the basis of these studies and previous stud- 
ies showing that ACE inhibitors improve exercise 
performance and symptoms in patients with syrup- 
tomatic left ventricular dysfunction [7,8], ACE inhibi- 
tors  in conjunction with diuretics with or without con- 
comitant therapy with digoxin have become the 
standard for care of patients with symptomatic left 
ventricular dysfunction unless contraindicated be- 
cause of hyperkalemia or not tolerated because of 
symptomatic hypotension, progressive renal  dysfunc- 
tion, angioedema, or intractable cough. The finding in 
randomized trials of a significant effect of ACE inhibi- 
tors on mortality and morbidity in patients with syrup- 
tomatic left ventricular dysfunction has prompted ef- 
forts to apply this s t ra tegy to the vast  majority of 
patients with asymptomatic left ventricular dysfunc- 
tion, who have up to now not been treated with an 
ACE inhibitor. 
While efforts to extend the use of ACE inhibitors 
to patients with asymptomatic left ventricular dys- 
function are important,  there is also evidence sug- 
gesting that  despite the use of ACE inhibitors in pa- 
tients with symptomatic left ventricular dysfunction, 
there remains a relatively high incidence of mortality 
and recurrent heart  failure [2]. This realization has 
prompted efforts to explore other mechanisms and 
t reatment  strategies, including the use of beta- 
adrenergic receptor blocking agents, inotropic agents, 
direct-acting vasodilators, and metabolically effective 
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agents, to further reduce mortality and morbidity [9]. 
One potential strategy to further improve mortality 
and morbidity in the patient with symptomatic left 
ventricular dysfunction has been largely overlooked, 
that is, blockade of aldosterone. 
Many clinicians have assumed that ACE inhibitor 
therapy would block both angiotensin II and aldoste- 
rone. However, there are data to suggest that aldo- 
sterone production remains important despite the use 
of an ACE inhibitor. After several months of ACE 
inhibitor therapy and continued inhibition of angioten- 
sin II production in patients with hypertension, aldo- 
sterone levels may increase or "escape" [10]. A similar 
escape of aldosterone production has recently been 
shown in patients with heart failure treated with an 
ACE inhibitor [11]. Recent studies have also shown 
that relatively high doses of an ACE inhibitor, such 
as captopril 50 mg three times daily for several days, 
suppresses resting levels of both angiotensin II and 
aldosterone, but during exercise both angiotensin II 
and aldosterone levels increase [12]. 
In another recent study using zofinopril in patients 
with acute myocardial infarction, it was shown that 
while ACE levels were almost completely suppressed 
angiotensin II and aldosterone levels escaped after 
several days [13]. The SOLVD trial has also sug- 
gested an escape of angiotensin II and catecholamine 
levels despite treatment with enalapril in doses of up 
to 10 mg bid after 1 year [14]. Although aldosterone 
levels were not measured in this study, it can be pos- 
tulated that if angiotensin II levels increase there 
would also be an increase in aldosterone levels. Thus 
there appears to be an "escape" of aldosterone produc- 
tion, and in some instances angiotensin II, despite 
continued use of an ACE inhibitor. The mechanisms 
for the "escape" of aldosterone and angiotensin II are 
incompletely understood. Alternative pathways for 
the production of angiotensin II have been identified 
[15,16] and may become important after prolonged 
blockade of ACE, with a resultant increase in renin. 
Aldosterone production may be stimulated by de- 
creased plasma levels of potassium and magnesium, 
and increased levels of ACTH, independent of the 
level of angiotensin II [17,18]. 
Aldosterone is produced in the zona glomerulosa of 
the adrenal gland [17-20]. Plasma aldosterone levels 
are normally between 5 and 15 ng/dl. Synthesis of 
aldosterone is mainly determined by angiotensin II. 
Other factors, such as an increase in ACTH, norepi- 
nephrine, or atrial naturietic factor, or a decrease in 
intracellular potassium and magnesium, are also of im- 
portance and may be critical in determining aldoste- 
rone synthesis in situations in which angiotensin II 
production is inhibited. Inactivation of aldosterone oc- 
curs mainly in the liver. Its metabolite tetrahydroal- 
dosterone is conjugated with glucuronic acid and ex- 
creted in the urine. Impaired hepatic blood flow and 
metabolism of aldosterone in the liver may also be of 
importance in determining serum aldosterone levels. 
In situations such as chronic heart failure, in which 
hepatic blood flow and metabolism are impaired, the 
plasma half-life of aldosterone may increase from a 
normal value of 30-35 minutes to over 70 minutes, 
with a concomitant increase in aldosterone levels from 
a normal range of 5-15 ng/dl to over 30 ng/dl. Con- 
versely, heparin, which blocks angiotensin II re- 
ceptors in the zona glomerulosa of the adrenal gland 
and digitalis, through action on sodium/potassium 
ATPase, intracellular sodium, and potassium concen- 
tration, may decrease aldosterone production [17,18]. 
The consequences of an elevation of angiotensin II 
levels are well known and include peripheral and coro- 
nary vasoconstriction, stimulation of growth factors 
[21], release of endothelin [22] and plasminogen acti- 
vator inhibitor [23], and oxidation of low density lipo- 
protein [24]. The effect of increased aldosterone pro- 
duction has, however, received less attention and will 
be briefly reviewed. An escape of aldosterone despite 
the use of an ACE inhibitor has several potentially 
important consequences that could result in the rela- 
tively high incidence of morbidity and mortality seen 
in patients with symptomatic left ventricular dysfunc- 
tion despite treatment with an ACE inhibitor. Aldo- 
sterone would be expected to play a role in recurrent 
heart failure through its well-known effects in promot- 
ing distal renal tubular sodium absorption [25]. Ele- 
vated levels of aldosterone have also been implicated, 
at least in animal models, in myocardial collagen pro- 
duction [26] and ventricular hypertrophy [27]. In- 
creased myocardial collagen production and conse- 
quent left ventricular hypertrophy could lead to an 
impairment in diastolic filling, diastolic dysfunction, 
and decreased coronary flow reserve, and eventually 
systolic dysfunction and recurrent heart failure. 
Aldosterone may also be of importance in the rela- 
tively high incidence of sudden cardiac death found 
in patients with both ischemic and nonischemic heart 
failure. Increased aldosterone levels cause a loss of 
potassium and magnesium from the distal renal tu- 
bule. Both hypokalemia and hypomagnesemia predis- 
pose to recurrent ventricular arrhythmias, digitalis 
toxicity, and therefore sudden cardiac death [28,29]. 
The use of adjunctive potassium is common in patients 
with heart failure treated with diuretics and digitalis; 
hypokalemia nevertheless remains a major problem. 
In part, the hypokalemia can be corrected by the con- 
comitant use of magnesium, which facilitates potas- 
sium retention [30]. Aldosterone may also predispose 
to ventricular arrhythmias through its effect on nor- 
epinephrine uptake [31]. 
Barr et al. have recently shown that norepineph- 
rine uptake, as assessed by the myocardial uptake of 
meta-iodobenzylguanidine (mlBG), is depressed in pa- 
tients with heart failure and that this can be improved 
by the use of the aldosterone receptor antagonist spi- 
ronolactone despite the use of an ACE inhibitor [31]. 
The finding in the SOLVD treatment trial [2] that 
sudden cardiac death was only minimally reduced by 
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enalapril and the failure of type I antiarrhythmic 
agents to reduce mortality in patients with left ven- 
tricular dysfunction in the Cardiac Arrhythmia Sup- 
pression Trial (CAST) [32] are an impetus to develop 
further strategies to prevent ventricular arrhythmias 
and sudden cardiac death in patients with left ventric- 
ular dysfunction. Although there is considerable con- 
troversy regarding the effectiveness of ACE inhibi- 
tors in reducing sudden cardiac death in that sudden 
cardiac death was found to be reduced in the V-HeFT 
II trial [33], sudden cardiac death nevertheless re- 
mains an important cause of death in patients with 
symptomatic left ventricular dysfunction treated with 
an ACE inhibitor. 
An escape of aldosterone could also play a role in 
recurrent ischemic events in patients with left yen- 
tricular dysfunction. The SOLVD trial pointed out the 
importance of recurrent ischemic events, myocardial 
infarction, and hospitalization for unstable angina in 
patients with left ventricular dysfunction due to isch- 
emic as well as nonischemic cardiomyopathy [6]. Pa- 
tients wtih recurrent ischemic events had a sever- 
alfold increase in the risk of death compared with 
patients without a recurrent ischemic event. Prior to 
this observation most clinicians focused on symptom- 
atic improvement in patients with left ventricular dys- 
function. The finding that recurrent ischemic events 
are common in both patients with ischemic as well as 
nonischemic cardiomyopathy has promoted efforts to 
prevent recurrent ischemia. Risk factor reduction in 
patients with ischemic cardiomyopathy, and correc- 
tion of recurrent ischemia by revascularization, de- 
serve increased emphasis. 
Of importance in the SOLVD treatment [2-6] and 
prevention trials [34], as well as in the SAVE trial 
[4], was the finding that ACE inhibitors were effective 
in preventing recurrent myocardial infarction. These 
findings are of particular importance both for the pa- 
gent with symptomatic left ventricular dysfunction as 
well as for the secondary prevention of ischemic heart 
disease in patients with asymptomatic left ventricular 
dysfunction, and have prompted a randomized trial to 
explore the role of ACE inhibitors in patients with 
ischemic heart disease and preserved left ventricular 
dysfunction (EF -> 40%) [35]. While the effectiveness 
of ACE inhibitors in preventing recurrent ischemic 
events can be explained by their effect in preventing 
angiotensin II production, there is evidence to sug- 
gest that aldosterone production might also be of im- 
portance and that an escape of aldosterone could pre- 
dispose to recurrent myocardial infarction. 
As mentioned earlier, aldosterone has been shown 
to cause left ventricular hypertrophy in experimental 
animals [26] and is significantly correlated with left 
ventricular mass in patients [36]. Left ventricular hy- 
pertrophy has been shown to be associated with a de- 
crease in coronary flow reserve [37]. A decrease in 
coronary flow reserve has been demonstrated in both 
patients with nonischemic and ischemic cardiomyopa- 
thy [38]. Prevention of left ventricular hypertrophy 
by ACE inhibitors and/or aldosterone receptor antag- 
onists could be expected to maintain coronary flow 
reserve and thereby prevent recurrent myocardial 
ischemia. 
There are, however, several other mechanisms 
whereby aldosterone could cause myocardial ischemia 
and infarction. Patients with primary aldosteronism 
have been found to have endothelial dysfunction, as 
evidenced by a decrease in forearm vascular response 
to the administration of acetylcholine as compared 
with normal individuals [39]. Removal of the aldoste- 
rone-producing tumor restores endothelial function. 
Endothelial dysfunction could be expected to lead to 
increased peripheral and coronary arterial resistance 
in response to neurohumoral stimuli such as angioten- 
sin II, norepinephrine, or release of platelet products 
such as thromboxane and serotonin, all of which are 
endothelial-dependent vasodilators. Endothelial dys- 
function has been suggested to be an important pre- 
cursor of atherosclerosis [40] and has been demon- 
strated in patients with heart failure [41]. Release of 
endothelin from the endothelium has been shown to 
increase aldosterone levels [42]. Endothelin is a po- 
tent growth factor stimulant [43] and could play a role 
in the development of atherosclerosis [44] directly 
and/or through release of aldosterone. 
Aldosterone has also been inversely correlated 
with serum high density lipoprotein cholesterol 
(HDL-C) concentrations [44]. A reduction in HDL-C 
concentration would be expected to predispose to ath- 
erosclerosis. A further potential link between aldoste- 
rone and atherosclerosis comes from the demonstra- 
tion that there are specific aldosterone receptors on 
monocytes and that aldosterone administration re- 
sults in an increase in intracellular monocyte calcium, 
sodium, and potassium [46,47]. The effect of these in- 
tracellular changes on electrolyte concentration are 
uncertain but could potentially influence monocyte 
function and/or cytokine release. 
Aldosterone might also predispose to recurrent 
ischemia and infarction through its effects on magne- 
sium. Individuals living in areas with low magnesium 
concentrations in their water have a significantly 
higher incidence of myocardial infarction than individ- 
uals living in areas with a high magnesium content 
[29]. Magnesium depletion in experimental animals 
has been shown to result in an increase in coronary 
vasomotor tone [47], and experimental hypomagnese- 
mia has been used to cause coronary arterial spasm 
[48]. Experimental magnesium depletion has also 
been shown to cause cytokine release, which could 
further depress myocardial function [49,50]. Patients 
with symptomatic left ventricular dysfunction treated 
with high doses of loop diuretics activate their renin 
angiotensin-aldosterone system [51] and would be ex- 
pected to have magnesium depletion. The incidence of 
magnesium depletion in patients with symptomatic 
left ventricular dysfunction treated with loop diuretics 
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is, however, controversial. Recent studies have not 
detected a high incidence of hypomagnesemia in pa- 
tients with chronic heart failure despite the use of loop 
diuretics [52,53]. While hypomagnesemia does not ap- 
pear to be common, despite the use of loop diuretics, 
there is evidence for a decrease in intracellular mag- 
nesium concentrations, which may not be reflected in 
serum levels [54]. The administration of magnesium 
supplementation to patients with chronic heart failure 
treated with loop diuretics has been shown to result 
in a significant reduction in complex ventricular ar- 
rhythmias [55]. 
Due to the mechanisms outlined earlier and the 
finding in the CONSENSUS trial that there was a 
significant correlation between aldosterone and mor- 
tality [56], it has been postulated that an aldosterone 
receptor blocking agent would be of benefit in reduc- 
ing the incidence of recurrent heart failure, ventricu- 
lar arrhythmias, ischemic events, and therefore death 
in patients with heart failure despite the use of con- 
ventional therapy including an ACE inhibitor. There 
is evidence that the addition of spironolactone, an al- 
dosterone receptor antagonist, to the therapy for pa- 
tients with severe heart failure treated with conven- 
tional therapy including diuretics, digoxin, and an 
ACE inhibitor results in increased diuresis and symp- 
tomatic improvement [57]. A high incidence of hyper- 
kalemia has not been observed in these patients de- 
spite concomitant treatment with an ACE inhibitor, 
nor in previous studies of patients with hypertension 
treated with an ACE inhibitor and aldactone. Never- 
theless, the relative paucity of data on the safety of 
spironolactone in patients with symptomatic left ven- 
tricular dysfunction treated with an ACE inhibitor 
has prompted a prospective blinded randomized inter- 
national multicenter study in order to explore its 
safety when used in conjunction with an ACE inhibi- 
tor, the Randomized Aldactone Evaluation Study 
(RALES Pilot Study). The data from this pilot safety 
study will be used to develop the dosing strategy for 
a subsequent study (RALES Mortality Trial) testing 
the efficacy of aldactone in reducing total mortality in 
patients with NYHA class IV heart failure treated 
with conventional therapy including an ACE inhibi- 
tor. 
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